<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619199</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180343</org_study_id>
    <secondary_id>2019-A00825-52</secondary_id>
    <nct_id>NCT04619199</nct_id>
  </id_info>
  <brief_title>Influence of Socioeconomic and Environmental Factors on the Natural History of Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>EXPOSOMFPI</acronym>
  <official_title>Influence of Socioeconomic and Environmental Factors on the Natural History of Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic Pulmonary Fibrosis(IPF) is the most common idiopathic interstitial lung disease&#xD;
      whose cause is unknown. With age and gender, socio-economic factors are the most influential&#xD;
      indicators of health. At present there is very little data on socio-economic factors in the&#xD;
      IPF. The investigators hypothesize that a lower socio-economic level and / or exposure to&#xD;
      various air pollutants may influence the IPF's natural history, including the severity of&#xD;
      diagnosis and prognosis of the IPF. The investigators also hypothesize that the deleterious&#xD;
      effect of air pollutants is modulated by individual susceptibility (shorter telomeres) and&#xD;
      that this effect is related to oxidative stress and shortening of telomeres.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic Pulmonary Fibrosis is the most common idiopathic interstitial lung disease whose&#xD;
      cause is unknown. However, it remains a rare disease, there is an incidence of approximately&#xD;
      4400 new patients per year in France. It is a serious disease with few therapeutic options&#xD;
      and a median survival after diagnosis around 36 months. It is also responsible for high&#xD;
      morbidity, with a marked deterioration in quality of life (dyspnea, cough, fatigue and&#xD;
      anxiodepressive disorders) and significant functional impairment (respiratory failure) With&#xD;
      age and gender, socio-economic factors are the most influential indicators of health. At&#xD;
      present there is very little data on socio-economic factors in the IPF. The investigators&#xD;
      hypothesize that a lower socio-economic level and / or exposure to various air pollutants may&#xD;
      influence the IPF's natural history, including the severity of diagnosis and prognosis of the&#xD;
      IPF. The investigators also hypothesize that the deleterious effect of air pollutants is&#xD;
      modulated by individual susceptibility (shorter telomeres) and that this effect is related to&#xD;
      oxidative stress and shortening of telomeres.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Longitudinal prospective cohort study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine if the household income is associated with the severity of the IPF at inclusion</measure>
    <time_frame>Enrollment</time_frame>
    <description>Patients will be classified into three groups: &quot;lower&quot; standard of living, &quot;average&quot; level and &quot;higher&quot; level. These groups are respectively defined by wages : less than 1000 euros, greater than or equal to 1000 euros and less than 4000 euros, and greater than or equal to 4000 euros.&#xD;
The severity of the IPF at baseline will be defined by the respiratory functional impact: a forced vital capacity (FVC) of less than 50% and / or a Carbon monoxide diffusion capacity of less than 30%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe the general and specific external environment of patients with IPF</measure>
    <time_frame>Enrollment</time_frame>
    <description>Collection of data on the general and specific external environment on patients with IPF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution) on the severity of the IPF</measure>
    <time_frame>Enrollment</time_frame>
    <description>Collection of data about socio-economic and environmental factors, and about severity on patients with IPF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution) on the quality of life</measure>
    <time_frame>Enrollment</time_frame>
    <description>Collection of data about socio-economic and environmental factors, and about quality of life on patients with IPF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution) on the occurrence of an Acute Exacerbation</measure>
    <time_frame>24 months</time_frame>
    <description>Collection of data about socio-economic and environmental factors, and about occurrence of an Acute Exacerbation on patients with IPF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution) on the progress of the IPF</measure>
    <time_frame>24 months</time_frame>
    <description>Collection of data about socio-economic and environmental factors, and about progression of IPF on patients with IPF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution) on the mortality</measure>
    <time_frame>24 months</time_frame>
    <description>Collection of data about socio-economic and environmental factors, and about mortality of patients with IPF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution)on the existence and type of comorbidities</measure>
    <time_frame>Enrollment</time_frame>
    <description>Collection of data about socio-economic and environmental factors, and about existence and type of comorbidities on patients with IPF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution)on the diagnostic and management delay</measure>
    <time_frame>Enrollment</time_frame>
    <description>Collection of data about socio-economic and environmental factors, and about diagnostic and management delay on patients with IPF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of socio-economic factors and environmental factors on therapeutic decisions: anti-fibrotic treatments, access to transplantation</measure>
    <time_frame>24 months</time_frame>
    <description>Collection of data about socio-economic and environmental factors (occupational domestic exposures and air pollution), and about therapeutic decisions (anti-fibrotic treatments, access to transplantation) on patients with IPF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine if the deleterious effect of air pollutants on the decline of respiratory function is dependent on the size of the telomeres</measure>
    <time_frame>24 months</time_frame>
    <description>Collection of data about deleterious effect of air pollutants on the decline of respiratory function and about the length of telomers calculated with T/S ratio. Blood samples will be performed for analysis of biomarkers and oxidative stress in IPF, measurement of telomere length, MUC5B, TOLLIP and GSTT1 polymorphisms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Pulmonary Disease</condition>
  <condition>Pulmonary Medicine</condition>
  <arm_group>
    <arm_group_label>Idiopathic Pulmonary Fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood sample were performed during the study for all patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sample performed at the inclusion and during the follow-up.</description>
    <arm_group_label>Idiopathic Pulmonary Fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man woman over 18 years old&#xD;
&#xD;
          -  Certain or probable Idiopathic Pulmonary Fibrosis determined by a multi-disciplinary&#xD;
             discussion (&quot;ATS / ERS / JRS / ALAT&quot; 2018 criteria)&#xD;
&#xD;
          -  Idiopathic Pulmonary Fibrosis with a diagnosis of less than 12 months&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patient affiliated to a social security scheme or universal health coverage or&#xD;
             benefiting from state medical aid&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known cause of Diffuse Interstitial Lung Disease (including connectivity,&#xD;
             Hypersensitivity pneumonitis or pneumoconiosis authenticated)&#xD;
&#xD;
          -  Patient unable to answer questionnaires&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Persons under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucile SESE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hilario NUNES, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nacira DARGHAL</last_name>
    <phone>(+33)148957473</phone>
    <email>nacira.darghal@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucile SESE, Dr</last_name>
    <phone>(+33)148955923</phone>
    <email>lucile.sese@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>001 - Service Pneumologie</name>
      <address>
        <city>Bobigny</city>
        <state>Avicenne</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hilario NUNES, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>002 - Service Explorations Fonctionnelles Respiratoires</name>
      <address>
        <city>Bobigny</city>
        <state>Avicenne</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lucile SESE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>003 - Service Pneumologie</name>
      <address>
        <city>Paris</city>
        <state>Bichat</state>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>016 - Service Pneumologie</name>
      <address>
        <city>Caen</city>
        <state>CHU Caen Normandie</state>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>010 - Service Pneumologie</name>
      <address>
        <city>Dijon</city>
        <state>CHU Dijon</state>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>013 - Service Pneumologie</name>
      <address>
        <city>Grenoble</city>
        <state>CHU Grenoble</state>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>008 - Service Pneumologie</name>
      <address>
        <city>Lille</city>
        <state>CHU Lille</state>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>015 - Service Pneumologie</name>
      <address>
        <city>Montpellier</city>
        <state>CHU Montpellier</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Arnaud BOURDIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>007 - Service Pneumologie</name>
      <address>
        <city>Rennes</city>
        <state>CHU Pontchaillou</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stéphane JOUNEAU, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>011 - Service Pneumologie</name>
      <address>
        <city>Strasbourg</city>
        <state>CHU Strasbourg</state>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>012 - Service Pneumologie</name>
      <address>
        <city>Tours</city>
        <state>CHU Tours</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sylvain MARCHAND-ADAM, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>014 - Service Pneumologie</name>
      <address>
        <city>Meaux</city>
        <state>Ghef</state>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>005 - Service Pneumologie</name>
      <address>
        <city>Paris</city>
        <state>Hegp</state>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>006 - Service Pneumologie</name>
      <address>
        <city>Lyon</city>
        <state>Hospices Civils De Lyon</state>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>004 - Service de Pneumologie</name>
      <address>
        <city>Paris</city>
        <state>Tenon</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacques CADRANEL, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>009 - Service Pneumologie</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Martine REYNAUT-GAUBERT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, Sanyal S, Brillet PY, Brauner M, Kambouchner M, Huynh S, Naccache JM, Borie R, Piquet J, Mekinian A, Virally J, Uzunhan Y, Cadranel J, Crestani B, Fain O, Lhote F, Dhote R, Saidenberg-Kermanac'h N, Rosental PA, Valeyre D, Nunes H. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J. 2017 Aug 3;50(2). pii: 1602419. doi: 10.1183/13993003.02419-2016. Print 2017 Aug.</citation>
    <PMID>28775045</PMID>
  </reference>
  <reference>
    <citation>Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.</citation>
    <PMID>21471066</PMID>
  </reference>
  <reference>
    <citation>Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ; American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19. doi: 10.1164/rccm.201506-1063ST. Erratum in: Am J Respir Crit Care Med. 2015 Sep 1;192(5):644. Dosage error in article text.</citation>
    <PMID>26177183</PMID>
  </reference>
  <reference>
    <citation>Cottin V. [French recommendations for idiopathic pulmonary fibrosis: An updated working document for clinicians]. Rev Mal Respir. 2017 Oct;34(8):789-790. doi: 10.1016/j.rmr.2017.09.005. French.</citation>
    <PMID>29102032</PMID>
  </reference>
  <reference>
    <citation>King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011 Dec 3;378(9807):1949-61. doi: 10.1016/S0140-6736(11)60052-4. Epub 2011 Jun 28. Review.</citation>
    <PMID>21719092</PMID>
  </reference>
  <reference>
    <citation>Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40. doi: 10.1164/rccm.201006-0894CI. Epub 2010 Oct 8. Review.</citation>
    <PMID>20935110</PMID>
  </reference>
  <reference>
    <citation>Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, Richeldi L, Taniguchi H, Martinez FJ. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75. doi: 10.1164/rccm.201604-0801CI. Review.</citation>
    <PMID>27299520</PMID>
  </reference>
  <reference>
    <citation>Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012 May 15;156(10):684-91. doi: 10.7326/0003-4819-156-10-201205150-00004.</citation>
    <PMID>22586007</PMID>
  </reference>
  <reference>
    <citation>Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015 Oct;46(4):1113-30. doi: 10.1183/13993003.02316-2014. Review.</citation>
    <PMID>26424523</PMID>
  </reference>
  <reference>
    <citation>Lantz PM, House JS, Lepkowski JM, Williams DR, Mero RP, Chen J. Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults. JAMA. 1998 Jun 3;279(21):1703-8.</citation>
    <PMID>9624022</PMID>
  </reference>
  <reference>
    <citation>Gershon AS, Dolmage TE, Stephenson A, Jackson B. Chronic obstructive pulmonary disease and socioeconomic status: a systematic review. COPD. 2012 Jun;9(3):216-26. doi: 10.3109/15412555.2011.648030. Epub 2012 Apr 12. Review.</citation>
    <PMID>22497534</PMID>
  </reference>
  <reference>
    <citation>Lederer DJ, Arcasoy SM, Barr RG, Wilt JS, Bagiella E, D'Ovidio F, Sonett JR, Kawut SM. Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. Am J Transplant. 2006 Oct;6(10):2436-42. Epub 2006 Jul 26.</citation>
    <PMID>16869805</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>socioeconomic Status</keyword>
  <keyword>air pollution</keyword>
  <keyword>Environmental exposure</keyword>
  <keyword>Occupational exposure</keyword>
  <keyword>idiopathic pulmonary fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

